Efficacy of intraarterial thrombolysis of basilar artery stroke

Robert Egan, Wayne Clark, Helmi Lutsep, Gary Nesbit, Stanley Barnwell, Jordi Kellogg

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Stroke from basilar artery (BA) occlusion is a devastating neurological event with reported mortality rates of up to 90%. This series reports our experience in 15 cases using intraarterial (IA) thrombolysis to treat basilar artery stroke at the Oregon Stroke Center. Methods: Over a 4-year period, consecutive cases of basilar artery stroke were treated with IA urokinase (UK) if they met the following criteria: had a baseline National Institutes of Health Stroke Scale (NIHSS) score greater than 6; symptoms began within 48 hours; had no or minimal early infarct signs on computed tomography (CT) scan; and angiogram confirmed basilar occlusion. Patients were treated with UK infused via a microcatheter directly into the clot. Angiographic efficacy was assessed by a repeat angiogram at the end of infusion and clinical efficacy was determined by NIHSS evaluation at 48 hours and 3 months. Results: Fifteen patients, mean age 59 (16 to 78) and baseline NIHSS of 30 (7 to 40), were treated at a mean of 12 hours (4 to 48). An average dose of 500,000 (150,000 to 1,250,000) units of UK was given over 1 to 2 hours. Excellent vessel recanalization occurred in 12 of 15 (80%) patients. All three cases without recanalization died within 48 hours (100%). Of the 12 patients with recanalization, 2 died (16.7%), whereas the 9 of 10 remaining had mild or moderate neurological deficits (mean NIHSS of 5) at 3 months. Conclusion: IA thrombolysis has the potential to decrease mortality and improve outcome in cases with severe basilar artery stroke even when administered after 6 hours.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalJournal of Stroke and Cerebrovascular Diseases
Volume8
Issue number1
DOIs
StatePublished - Jan 1999

Fingerprint

Basilar Artery
Stroke
National Institutes of Health (U.S.)
Urokinase-Type Plasminogen Activator
Angiography
Mortality
Tomography

Keywords

  • Basilar
  • Stroke
  • Thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of intraarterial thrombolysis of basilar artery stroke. / Egan, Robert; Clark, Wayne; Lutsep, Helmi; Nesbit, Gary; Barnwell, Stanley; Kellogg, Jordi.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 8, No. 1, 01.1999, p. 22-27.

Research output: Contribution to journalArticle

Egan, Robert ; Clark, Wayne ; Lutsep, Helmi ; Nesbit, Gary ; Barnwell, Stanley ; Kellogg, Jordi. / Efficacy of intraarterial thrombolysis of basilar artery stroke. In: Journal of Stroke and Cerebrovascular Diseases. 1999 ; Vol. 8, No. 1. pp. 22-27.
@article{743bdb0ee9eb4e24bc4d1d866f7cb8a1,
title = "Efficacy of intraarterial thrombolysis of basilar artery stroke",
abstract = "Background: Stroke from basilar artery (BA) occlusion is a devastating neurological event with reported mortality rates of up to 90{\%}. This series reports our experience in 15 cases using intraarterial (IA) thrombolysis to treat basilar artery stroke at the Oregon Stroke Center. Methods: Over a 4-year period, consecutive cases of basilar artery stroke were treated with IA urokinase (UK) if they met the following criteria: had a baseline National Institutes of Health Stroke Scale (NIHSS) score greater than 6; symptoms began within 48 hours; had no or minimal early infarct signs on computed tomography (CT) scan; and angiogram confirmed basilar occlusion. Patients were treated with UK infused via a microcatheter directly into the clot. Angiographic efficacy was assessed by a repeat angiogram at the end of infusion and clinical efficacy was determined by NIHSS evaluation at 48 hours and 3 months. Results: Fifteen patients, mean age 59 (16 to 78) and baseline NIHSS of 30 (7 to 40), were treated at a mean of 12 hours (4 to 48). An average dose of 500,000 (150,000 to 1,250,000) units of UK was given over 1 to 2 hours. Excellent vessel recanalization occurred in 12 of 15 (80{\%}) patients. All three cases without recanalization died within 48 hours (100{\%}). Of the 12 patients with recanalization, 2 died (16.7{\%}), whereas the 9 of 10 remaining had mild or moderate neurological deficits (mean NIHSS of 5) at 3 months. Conclusion: IA thrombolysis has the potential to decrease mortality and improve outcome in cases with severe basilar artery stroke even when administered after 6 hours.",
keywords = "Basilar, Stroke, Thrombolysis",
author = "Robert Egan and Wayne Clark and Helmi Lutsep and Gary Nesbit and Stanley Barnwell and Jordi Kellogg",
year = "1999",
month = "1",
doi = "10.1016/S1052-3057(99)80035-4",
language = "English (US)",
volume = "8",
pages = "22--27",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy of intraarterial thrombolysis of basilar artery stroke

AU - Egan, Robert

AU - Clark, Wayne

AU - Lutsep, Helmi

AU - Nesbit, Gary

AU - Barnwell, Stanley

AU - Kellogg, Jordi

PY - 1999/1

Y1 - 1999/1

N2 - Background: Stroke from basilar artery (BA) occlusion is a devastating neurological event with reported mortality rates of up to 90%. This series reports our experience in 15 cases using intraarterial (IA) thrombolysis to treat basilar artery stroke at the Oregon Stroke Center. Methods: Over a 4-year period, consecutive cases of basilar artery stroke were treated with IA urokinase (UK) if they met the following criteria: had a baseline National Institutes of Health Stroke Scale (NIHSS) score greater than 6; symptoms began within 48 hours; had no or minimal early infarct signs on computed tomography (CT) scan; and angiogram confirmed basilar occlusion. Patients were treated with UK infused via a microcatheter directly into the clot. Angiographic efficacy was assessed by a repeat angiogram at the end of infusion and clinical efficacy was determined by NIHSS evaluation at 48 hours and 3 months. Results: Fifteen patients, mean age 59 (16 to 78) and baseline NIHSS of 30 (7 to 40), were treated at a mean of 12 hours (4 to 48). An average dose of 500,000 (150,000 to 1,250,000) units of UK was given over 1 to 2 hours. Excellent vessel recanalization occurred in 12 of 15 (80%) patients. All three cases without recanalization died within 48 hours (100%). Of the 12 patients with recanalization, 2 died (16.7%), whereas the 9 of 10 remaining had mild or moderate neurological deficits (mean NIHSS of 5) at 3 months. Conclusion: IA thrombolysis has the potential to decrease mortality and improve outcome in cases with severe basilar artery stroke even when administered after 6 hours.

AB - Background: Stroke from basilar artery (BA) occlusion is a devastating neurological event with reported mortality rates of up to 90%. This series reports our experience in 15 cases using intraarterial (IA) thrombolysis to treat basilar artery stroke at the Oregon Stroke Center. Methods: Over a 4-year period, consecutive cases of basilar artery stroke were treated with IA urokinase (UK) if they met the following criteria: had a baseline National Institutes of Health Stroke Scale (NIHSS) score greater than 6; symptoms began within 48 hours; had no or minimal early infarct signs on computed tomography (CT) scan; and angiogram confirmed basilar occlusion. Patients were treated with UK infused via a microcatheter directly into the clot. Angiographic efficacy was assessed by a repeat angiogram at the end of infusion and clinical efficacy was determined by NIHSS evaluation at 48 hours and 3 months. Results: Fifteen patients, mean age 59 (16 to 78) and baseline NIHSS of 30 (7 to 40), were treated at a mean of 12 hours (4 to 48). An average dose of 500,000 (150,000 to 1,250,000) units of UK was given over 1 to 2 hours. Excellent vessel recanalization occurred in 12 of 15 (80%) patients. All three cases without recanalization died within 48 hours (100%). Of the 12 patients with recanalization, 2 died (16.7%), whereas the 9 of 10 remaining had mild or moderate neurological deficits (mean NIHSS of 5) at 3 months. Conclusion: IA thrombolysis has the potential to decrease mortality and improve outcome in cases with severe basilar artery stroke even when administered after 6 hours.

KW - Basilar

KW - Stroke

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0002549454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002549454&partnerID=8YFLogxK

U2 - 10.1016/S1052-3057(99)80035-4

DO - 10.1016/S1052-3057(99)80035-4

M3 - Article

AN - SCOPUS:0002549454

VL - 8

SP - 22

EP - 27

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 1

ER -